Public Profile

Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Inc., a leading biopharmaceutical company headquartered in the United States, focuses on developing innovative treatments for skin diseases. Founded in 2018, Verrica has quickly established itself in the dermatology sector, particularly in the treatment of conditions such as molluscum contagiosum. The company’s flagship product, VP-102, is a unique topical therapy that utilises a proprietary formulation to effectively target viral skin infections. This innovative approach sets Verrica apart in a competitive market, positioning it as a key player in dermatological therapeutics. With a commitment to advancing patient care, Verrica Pharmaceuticals continues to make significant strides in the industry, aiming to improve the quality of life for those affected by challenging skin conditions.

DitchCarbon Score

How does Verrica Pharmaceuticals Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

13

Industry Average

Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

2

Industry Benchmark

Verrica Pharmaceuticals Inc.'s score of 13 is higher than 60% of the industry. This can give you a sense of how well the company is doing compared to its peers.

60%

Verrica Pharmaceuticals Inc.'s reported carbon emissions

Verrica Pharmaceuticals Inc., headquartered in the US, currently does not have publicly available carbon emissions data or specific reduction targets. As a result, there are no reported figures for their Scope 1, 2, or 3 emissions. The absence of emissions data suggests that the company may still be in the early stages of developing its climate commitments or reporting practices. In the context of the pharmaceutical industry, many companies are increasingly focusing on sustainability and climate action, often setting ambitious targets to reduce their carbon footprint. However, without specific initiatives or commitments disclosed by Verrica Pharmaceuticals, it is unclear how they plan to address climate change or contribute to emissions reduction efforts.

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Verrica Pharmaceuticals Inc.'s primary industry is Chemicals nec, which is medium in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. Verrica Pharmaceuticals Inc. is headquartered in US, which has a rank of low, indicating low grid carbon intensity.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Verrica Pharmaceuticals Inc. is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
Carbon Disclosure Project
The Climate Pledge
UN Global Compact

Similar Organizations

MC2 Therapeutics A/S

DK
Other services (93)
Updated 2 days ago

VYNE Therapeutics Inc.

US
Chemicals nec
Updated 5 days ago

Leo Pharma

DK
Medical, precision and optical instruments, watches and clocks (33)
Updated about 14 hours ago

Mayne Pharma

AU
Medical, precision and optical instruments, watches and clocks (33)
Updated 2 days ago

Dermavant Sciences Ltd.

GB
Health and social work services (85)
Updated 2 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers